


## GUEST EDITOR

*Oncogene* (2009) 27, S1; doi:10.1038/onc.2009.38



**Dr G Chinnadurai**

G Chinnadurai obtained his PhD in Molecular Biology from the University of Texas in Dallas in 1974. He conducted his Post-Doctoral research at the Institute for Molecular Virology, Saint Louis University School of Medicine, with Dr Maurice Green, continued in the same institution as a faculty member and was appointed as Professor of Molecular Virology in 1983. Dr Chinnadurai's research focuses on two areas: apoptosis regulation by viral and cellular genes, and mechanisms of oncogenic transformation. The research on these projects centers around two adenoviral early proteins, E1A and E1B-19K. His work on apoptosis regulation in

adenovirus-infected cells started with the isolation and mapping of large plaque (*lp*) mutants of adenovirus type 2 to the E1B-19K-coding region. This work associated E1B-19K with a large plaque phenotype and facilitated the linking of an earlier known class of cytopathic (*cyt*) mutants to the *19K* locus. He then established the functional similarity between E1B-19K and BCL-2 on the basis of genetic complementation analyses, in which the *19K* mutant phenotype was shown to be suppressed in cells that overexpressed BCL-2 and in cells infected with a recombinant adenovirus that expressed BCL-2 from the E1B region. An important outcome was the identification and characterization of four cellular proteins that interact with E1B-19K and BCL-2. One of these proteins is the founding member of the BH3-only family of proteins, BIK. This class of proteins functions as apical effector of apoptosis in animal cells. The other 19K/BCL-2-interacting proteins are two other BH3-only members, BNIP3 and BNIP1, and BNIP2, a pro-apoptotic regulator of Cdc42. During mapping of the *lp* locus, Dr Chinnadurai also developed the overlap recombination method to construct adenovirus recombinants by transfection of overlapping DNA fragments. This method has been used widely in adenovirology and adenovirus-based gene therapy approaches. Of considerable note, his work on E1A identified a transformation suppression and tumor-restraining activity encoded by the C-terminal region of E1A. This work led to the identification of a novel transcriptional co-repressor, CtBP (C-terminal Binding Protein), which is essential for animal development and represses multiple tumor suppressors, pro-apoptotic genes and epithelial differentiation genes. His group also identified the pivotal cellular regulators, the acetyl transferase, Tip60, and the DNA repair protein, CtIP.

**Conflict of interest**

The author is currently receiving grant support from the National Cancer Institute (NCI, Rockville, MD, USA).